Get the Stockscreener App
4.72
3.28%
-0.16
Werewolf Therapeutics Inc stock is currently priced at $4.72, with a 24-hour trading volume of 114.62K.
It has seen a -3.28% decreased in the last 24 hours and a -19.18% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.85 pivot point. If it approaches the $4.67 support level, significant changes may occur.
Previous Close:
$4.88
Open:
$4.87
24h Volume:
114.62K
Market Cap:
$205.11M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-3.7165
EPS:
-1.27
Net Cash Flow:
$-33.38M
1W Performance:
-6.53%
1M Performance:
-19.18%
6M Performance:
+105.22%
1Y Performance:
+72.26%
1D Range:
$4.72
$4.96
52W Range:
$1.5735
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617 952 0555
Address
1030 Massachusetts Avenue, Suite 210, Cambridge
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics (HOWL) Stock Forecast and Price Target 2024 - MarketBeat
MarketBeat
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Forecasted to Earn Q2 2024 Earnings of ($0.40) Per Share - MarketBeat
MarketBeat
HC Wainwright Weighs in on Werewolf Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:HOWL) - Defense World
Defense World
Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Werewolf Therapeutics (NASDAQ:HOWL) Given Market Outperform Rating at JMP Securities - Defense World
Defense World
(HOWL) Investment Report - Stock Traders Daily
Stock Traders Daily
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Werewolf Therapeutics Inc (HOWL) Revenue 2024
HOWL reported a revenue (TTM) of $19.94 million for the quarter ending December 31, 2023.
Werewolf Therapeutics Inc (HOWL) Net Income 2024
HOWL net income (TTM) was -$37.37 million for the quarter ending December 31, 2023, a +30.56% increase year-over-year.
Werewolf Therapeutics Inc (HOWL) Cash Flow 2024
HOWL recorded a free cash flow (TTM) of -$33.38 million for the quarter ending December 31, 2023, a +24.49% increase year-over-year.
Werewolf Therapeutics Inc (HOWL) Earnings per Share 2024
HOWL earnings per share (TTM) was -$1.04 for the quarter ending December 31, 2023, a +44.68% growth year-over-year.
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
0.77%
1.20%
Cap:
|
Volume (24h):